• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Recent Advances in the Study of 3-Chloroimidazo[1,5-a]pyridine (CAS: 1895224-02-8) in Chemical Biology and Pharmaceutical Research

3-Chloroimidazo[1,5-a]pyridine (CAS: 1895224-02-8) is a heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and drug discovery. This compound serves as a key intermediate in the synthesis of various biologically active molecules, particularly those targeting kinase inhibitors and other therapeutic agents. Recent studies have explored its potential in modulating protein-protein interactions and its role in the development of novel anticancer and anti-inflammatory drugs.

A study published in the Journal of Medicinal Chemistry (2023) highlighted the synthesis and evaluation of 3-Chloroimidazo[1,5-a]pyridine derivatives as potent inhibitors of cyclin-dependent kinases (CDKs). The researchers employed a structure-activity relationship (SAR) approach to optimize the compound's binding affinity and selectivity. The results demonstrated that specific modifications to the imidazopyridine core significantly enhanced inhibitory activity against CDK4/6, which are critical targets in cancer therapy. These findings underscore the compound's potential as a scaffold for developing next-generation CDK inhibitors.

In another recent investigation, scientists explored the use of 3-Chloroimidazo[1,5-a]pyridine in the design of small-molecule modulators for inflammatory pathways. The study, published in Bioorganic & Medicinal Chemistry Letters (2024), revealed that derivatives of this compound exhibited strong inhibitory effects on NF-κB signaling, a pathway implicated in chronic inflammatory diseases. The researchers utilized computational docking studies to elucidate the binding modes of these derivatives, providing insights into their mechanism of action and paving the way for further optimization.

Furthermore, advancements in synthetic methodologies have facilitated the efficient production of 3-Chloroimidazo[1,5-a]pyridine and its derivatives. A recent report in Organic Process Research & Development (2023) described a scalable and environmentally friendly synthesis route, employing catalytic C-H activation strategies. This innovation not only improves the accessibility of the compound for research purposes but also aligns with the growing emphasis on sustainable chemistry practices in the pharmaceutical industry.

The pharmacokinetic properties of 3-Chloroimidazo[1,5-a]pyridine derivatives have also been a focus of recent research. A preclinical study published in European Journal of Pharmaceutical Sciences (2024) evaluated the absorption, distribution, metabolism, and excretion (ADME) profiles of selected derivatives. The results indicated favorable oral bioavailability and metabolic stability, suggesting their potential as viable drug candidates. However, the study also identified areas for further optimization, such as reducing off-target effects and improving tissue penetration.

In conclusion, 3-Chloroimidazo[1,5-a]pyridine (CAS: 1895224-02-8) continues to be a promising scaffold in chemical biology and pharmaceutical research. Recent studies have expanded our understanding of its therapeutic potential, particularly in oncology and inflammation. The development of novel synthetic routes and the elucidation of its mechanism of action further enhance its value as a tool compound and drug candidate. Future research should focus on translating these findings into clinical applications and addressing remaining challenges in drug development.

• 34108-92-4(2-chloro-1H-Naphth[1,2-d]imidazole)
• 117870-87-8(Benzimidazolyl, 2-chloro-)
• 918340-50-8(1-chloro-Pyrrolo[1,2-c]pyrimidine)
• 1234616-61-5(2-Chloropyrido[3,4-d]pyrimidine)
• 71670-67-2(1H-Naphth[2,3-d]imidazole,2-chloro-)
• 915302-21-5(Pyrido[3,2-d]pyrimidine, 2-chloro-)
• 2208-73-3(Cycloheptimidazole, 2-chloro-)
• 760912-66-1(2-Chloro-3H-imidazo[4,5-c]pyridine)
• 4857-06-1(2-Chlorobenzimidazole)
• 56481-39-1(3-chloro-Imidazo[1,5-a]pyrazine)